Cargando…
2262. Evaluation of Ceftriaxone Versus Cefazolin as a Surrogate Marker for Cefpodoxime Susceptibility in Enterobacterales Isolates
BACKGROUND: Cefpodoxime is increasingly being explored as an option for intravenous-to-oral step-down therapy in Enterobacterales infections, but it is rarely included in routine susceptibility testing. The Clinical and Laboratory Standards Institute (CLSI) states that cefpodoxime susceptibility amo...
Autores principales: | Lambert, Kaitlyn, Demkowicz, Ryan, Slain, Douglas, Murray, Amanda, Howard, Catessa A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678582/ http://dx.doi.org/10.1093/ofid/ofad500.1884 |
Ejemplares similares
-
266. Ceftriaxone Versus Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia
por: Mohamed, Adham, et al.
Publicado: (2020) -
1057. Treatment Efficacy of Ceftriaxone vs. Cefazolin for Methicillin-Susceptible Staphylococcus aureus Infections
por: Bhavan, Kavita, et al.
Publicado: (2018) -
274. Comparison of Cefazolin Susceptibilities of Enterobacterales with an Automated Susceptibility Testing Platform versus In Vitro Antimicrobial Testing
por: Noval, Mandee, et al.
Publicado: (2020) -
Ceftriaxone and cefazolin attenuate the cue-primed reinstatement of alcohol-seeking
por: Weiland, Ana, et al.
Publicado: (2015) -
256. Serratia Marcescens Bacteremia and Endocarditis: A Treatment Assessment from an Academic Medical Center
por: Slain, Douglas, et al.
Publicado: (2020)